Literature DB >> 20805909

Anchoring perceptions of clinical change on accurate recollection of the past: memory enhanced retrospective evaluation of treatment (MERET).

James C Mundt1, David J Debrota, John H Greist.   

Abstract

OBJECTIVE: To evaluate patients' self-reports of treatment efficacy with and without self-prompted memory aids regarding their clinical experiences obtained prior to treatment initiation.
DESIGN: Double-blind, placebo-controlled trial with variable expected duration placebo lead-in and washout.
SETTING: Multisite (US) randomized clinical trial. PARTICIPANTS: Seventy-four patients with initial or recurrent DSM-IV diagnosis of major depression with symptoms of at least four weeks duration. A minimum Clinical Global Impression of Severity rating of Moderately Depressed and a clinician 17-item Hamilton Rating Scale for Depression score of 15 or greater, with the depressed mood item score of at least 2 were required for study entry. MEASUREMENTS: Patient global impression of improvement (PGI-I) ratings obtained using an interactive voice response (IVR) computer-automated telephone system prior to and following playback of impromptu patient recordings obtained prior to the start of treatment (MERET).
RESULTS: MERET PGI-I ratings differentiated the effects of drug treatment from placebo more effectively than did standard PGI-I ratings. The drug-placebo treatment effect size obtained using standard PGI-I ratings was 0.525, whereas the effect size with MERET PGI-I ratings was 0.612.
CONCLUSION: The enhanced drug-placebo separation appeared to be primarily due to increased patients' perceptions of drug treatment effectiveness. Patients perceiving the greatest degree of clinical improvement indicated more benefit from hearing the MERET recordings. MERET appears to be a viable method for enhancing patients' insights into the benefits of effective treatments by allowing them to use personal descriptions provided in their own words and voice.

Entities:  

Keywords:  IVR; MERET; clinical trial; methodology; patient-reported outcomes

Year:  2007        PMID: 20805909      PMCID: PMC2922357     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  12 in total

1.  Patient and rater education of expectations in clinical trials (PREECT).

Authors:  D L Zimbroff
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

2.  Factors contributing to failed trials of new agents: can technology prevent some problems?

Authors:  John H Greist; James C Mundt; Kenneth Kobak
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

3.  Capturing the patient's view of change as a clinical outcome measure.

Authors:  D Fischer; A L Stewart; D A Bloch; K Lorig; D Laurent; H Holman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

4.  Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.

Authors:  Arif Khan; Robyn M Leventhal; Shirin R Khan; Walter A Brown
Journal:  J Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.153

5.  Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Authors:  Michael J Detke; Curtis G Wiltse; Craig H Mallinckrodt; Robert K McNamara; Mark A Demitrack; Istvan Bitter
Journal:  Eur Neuropsychopharmacol       Date:  2004-12       Impact factor: 4.600

6.  The responsiveness of the Hamilton Depression Rating Scale.

Authors:  D Faries; J Herrera; J Rayamajhi; D DeBrota; M Demitrack; W Z Potter
Journal:  J Psychiatr Res       Date:  2000 Jan-Feb       Impact factor: 4.791

7.  Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Authors:  James W Jefferson; A John Rush; J Craig Nelson; Susan A VanMeter; Alok Krishen; Kenneth D Hampton; Donna S Wightman; Jack G Modell
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

8.  Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.

Authors:  A John Rush; Madhukar H Trivedi; Thomas J Carmody; Hisham M Ibrahim; John C Markowitz; Gabor I Keitner; Susan G Kornstein; Bruce Arnow; Daniel N Klein; Rachel Manber; David L Dunner; Alan J Gelenberg; James H Kocsis; Charles B Nemeroff; Jan Fawcett; Michael E Thase; James M Russell; Darlene N Jody; Frances E Borian; Martin B Keller
Journal:  Neuropsychopharmacology       Date:  2005-02       Impact factor: 7.853

9.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.

Authors:  M H Trivedi; A J Rush; H M Ibrahim; T J Carmody; M M Biggs; T Suppes; M L Crismon; K Shores-Wilson; M G Toprac; E B Dennehy; B Witte; T M Kashner
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

10.  Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Authors:  Michael J Detke; Yili Lu; David J Goldstein; Robert K McNamara; Mark A Demitrack
Journal:  J Psychiatr Res       Date:  2002 Nov-Dec       Impact factor: 4.791

View more
  5 in total

1.  Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.

Authors:  Stephen Brunton; Fujun Wang; S Beth Edwards; Antonio S Crucitti; Melissa J Ossanna; Daniel J Walker; Michael J Robinson
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

2.  Vocal acoustic biomarkers of depression severity and treatment response.

Authors:  James C Mundt; Adam P Vogel; Douglas E Feltner; William R Lenderking
Journal:  Biol Psychiatry       Date:  2012-04-26       Impact factor: 13.382

3.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Proof-of-Concept Study: a Mobile Application to Derive Clinical Outcome Measures from Expression and Speech for Mental Health Status Evaluation.

Authors:  Francesco Luke Siena; Michael Vernon; Paul Watts; Bill Byrom; David Crundall; Philip Breedon
Journal:  J Med Syst       Date:  2020-11-11       Impact factor: 4.460

5.  The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.

Authors:  David G Perahia; Mark E Bangs; Qi Zhang; Yingkai Cheng; Jonna Ahl; Elijah P Frakes; Michael J Adams; James M Martinez
Journal:  Drug Healthc Patient Saf       Date:  2013-11-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.